101 related articles for article (PubMed ID: 31487248)
21. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents.
West DC; Shamberger RC; Macklis RM; Kozakewich HP; Wayne AS; Kreissman SG; Korf BR; Lavally B; Grier HE
J Clin Oncol; 1993 Jan; 11(1):84-90. PubMed ID: 8418247
[TBL] [Abstract][Full Text] [Related]
22. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992.
Cotterill SJ; Pearson AD; Pritchard J; Foot AB; Roald B; Kohler JA; Imeson J
Eur J Cancer; 2000 May; 36(7):901-8. PubMed ID: 10785596
[TBL] [Abstract][Full Text] [Related]
23. Role of surgery in the treatment of patients with high-risk neuroblastoma who have a poor response to induction chemotherapy.
Du L; Liu L; Zhang C; Cai W; Wu Y; Wang J; Lv F
J Pediatr Surg; 2014 Apr; 49(4):528-33. PubMed ID: 24726106
[TBL] [Abstract][Full Text] [Related]
24. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.
London WB; Castleberry RP; Matthay KK; Look AT; Seeger RC; Shimada H; Thorner P; Brodeur G; Maris JM; Reynolds CP; Cohn SL
J Clin Oncol; 2005 Sep; 23(27):6459-65. PubMed ID: 16116153
[TBL] [Abstract][Full Text] [Related]
25. Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma.
Spitz R; Hero B; Simon T; Berthold F
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3368-73. PubMed ID: 16740759
[TBL] [Abstract][Full Text] [Related]
26. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.
Meany HJ; London WB; Ambros PF; Matthay KK; Monclair T; Simon T; Garaventa A; Berthold F; Nakagawara A; Cohn SL; Pearson AD; Park JR
Pediatr Blood Cancer; 2014 Nov; 61(11):1932-9. PubMed ID: 25044743
[TBL] [Abstract][Full Text] [Related]
27. 3-Methoxytyramine: An independent prognostic biomarker that associates with high-risk disease and poor clinical outcome in neuroblastoma patients.
Verly IRN; van Kuilenburg ABP; Abeling NGGM; Goorden SMI; Fiocco M; Vaz FM; van Noesel MM; Zwaan CM; Kaspers GJL; Merks JHM; Caron HN; Tytgat GAM
Eur J Cancer; 2018 Feb; 90():102-110. PubMed ID: 29274926
[TBL] [Abstract][Full Text] [Related]
28. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.
Schmidt ML; Lal A; Seeger RC; Maris JM; Shimada H; O'Leary M; Gerbing RB; Matthay KK
J Clin Oncol; 2005 Sep; 23(27):6474-80. PubMed ID: 16116154
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
30. Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?
Di Cataldo A; Agodi A; Balaguer J; Garaventa A; Barchitta M; Segura V; Bianchi M; Castel V; Castellano A; Cesaro S; Couselo JM; Cruz O; D'Angelo P; De Bernardi B; Donat J; de Andoin NG; Hernandez MI; La Spina M; Lillo M; Lopez-Almaraz R; Luksch R; Mastrangelo S; Mateos E; Molina J; Moscheo C; Mura R; Porta F; Russo G; Tondo A; Torrent M; Vetrella S; Villegas JA; Viscardi E; Zanazzo GA; Cañete A
Clin Transl Oncol; 2017 Jan; 19(1):76-83. PubMed ID: 27041689
[TBL] [Abstract][Full Text] [Related]
31. Localised and unresectable neuroblastoma in infants: excellent outcome with primary chemotherapy. Neuroblastoma Study Group, Société Française d'Oncologie Pédiatrique.
Rubie H; Plantaz D; Coze C; Michon J; Frappaz D; Baranzelli MC; Chastagner P; Peyroulet MC; Hartmann O;
Med Pediatr Oncol; 2001 Jan; 36(1):247-50. PubMed ID: 11464897
[TBL] [Abstract][Full Text] [Related]
32. Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma.
De Bernardi B; Conte M; Mancini A; Donfrancesco A; Alvisi P; Tomà P; Casale F; Cordero di Montezemolo L; Cornelli PE; Carli M
J Clin Oncol; 1995 Apr; 13(4):884-93. PubMed ID: 7707115
[TBL] [Abstract][Full Text] [Related]
33. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
34. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.
Oberthuer A; Juraeva D; Hero B; Volland R; Sterz C; Schmidt R; Faldum A; Kahlert Y; Engesser A; Asgharzadeh S; Seeger R; Ohira M; Nakagawara A; Scaruffi P; Tonini GP; Janoueix-Lerosey I; Delattre O; Schleiermacher G; Vandesompele J; Speleman F; Noguera R; Piqueras M; Bénard J; Valent A; Avigad S; Yaniv I; Grundy RG; Ortmann M; Shao C; Schwab M; Eils R; Simon T; Theissen J; Berthold F; Westermann F; Brors B; Fischer M
Clin Cancer Res; 2015 Apr; 21(8):1904-15. PubMed ID: 25231397
[TBL] [Abstract][Full Text] [Related]
35. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
Schmidt ML; Lukens JN; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Perez C; Haase GM; Matthay KK
J Clin Oncol; 2000 Mar; 18(6):1260-8. PubMed ID: 10715296
[TBL] [Abstract][Full Text] [Related]
36. Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial.
Simon T; Hero B; Benz-Bohm G; von Schweinitz D; Berthold F
Pediatr Blood Cancer; 2008 May; 50(5):965-9. PubMed ID: 17914735
[TBL] [Abstract][Full Text] [Related]
37. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
[TBL] [Abstract][Full Text] [Related]
38. [Long-term follow-ups of comprehensive therapies for stage 4 neuroblastoma].
Zhang A; Pan C; Ye Q; Zhou M; Chen J; Luo C; Wang J; Tang Y; Xue H; Shen S; Tang J
Zhonghua Yi Xue Za Zhi; 2014 May; 94(20):1547-52. PubMed ID: 25146742
[TBL] [Abstract][Full Text] [Related]
39. [Neuroblastoma: prognostic factors and survival. Experience in Hospital de Pediatria del Centro Medico Nacional del Siglo XXI and review of the literature].
López-Aguilar E; Cerecedo-Díaz F; Rivera-Márquez H; Valdéz-Sánchez M; Sepúlveda-Vildósola AC; Delgado Huerta S; Vera-Hermosillo H; Vázquez-Langle JR; Wanzke del Angel V
Gac Med Mex; 2003; 139(3):209-14. PubMed ID: 12872413
[TBL] [Abstract][Full Text] [Related]
40. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group.
Strother D; van Hoff J; Rao PV; Smith EI; Shamberger RC; Halperin EC; Murray KJ; Castleberry RP
Eur J Cancer; 1997 Oct; 33(12):2121-5. PubMed ID: 9516866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
